1. Get more info on this report!
H1N1 (Swine Influenza) Market Assessment (Latest Data, Company
Profiles, Implications for Immunoassays and Molecular Assays)
May 1, 2009
The outbreak of H1N1 (swine flu) highlighted the public health importance of improved
testing techniques and providing market opportunities for manufacturers of diagnostic
tests and other products related to the disease. These conclusions and others appear in
a new report released from Kalorama Information: Swine Flu Market Alert by
Kalorama's lead analyst, Shara Rosen.
Regardless of the eventual severity of the epidemic, there will be distinct market impact
on both immunoassay and molecular test makers, according to the report. The makers
of certain tests will benefit both in terms of sales and more broadly in recognition that
their products play a vital role in making the public health community significantly better
prepared for this possible pandemic than 1968 or before.
The report examines:
Market Impact likely for immunoassays and molecular testing.
Lessons from previous epidemics, likely impact on both immunoassays and
molecular testing.
Overview of the H1N1 strain as compared to other.
Immunoassay and Molecular Test Products Available on the Market
Developments in the last few days of significance to the diagnostic industry.
Profiles of nearly 25 specific manufacturers active in this space.
The report focuses almost exclusively on the in vitro diagnostic industry as it applies to
work being done by commercial entities and products that are either in development or
have been brought to market.
The market assessment provided has been assembled based on publicly available
information. Company sales data and other quantitative evaluations of the markets for
flu diagnostics have been developed based on publicly available information and are
expressed in US dollars, no adjustments have been made for currency exchange
fluctuations.
Under normal circumstances, a report of this genre would be assembled from
information derived from primary and secondary sources. However, in the short time it

2. took to research and write this report, almost all of the major scientific and industry
experts were occupied with the extraordinary task of preparing for a pandemic.
Therefore the information contained in this report has been assembled from a vast array
of scientific and market publications, government sources, analyzed by a professional
analyst.
TABLE OF CONTENTS
CHAPTER ONE: EXECUTIVE SUMMARY
Background
Exhibit 1: Flu Epidemics Compared to Present 1918-Today
Scope And Methodology
Point of View
Information Sources
CHAPTER TWO: 2009 SWINE INFLUENZA AND OTHER FLU EPIDEMICS
Influenza Overview
Overview of Virus Types
What’s So Special About This Latest Flu?
Flu Therapeutics
WHO Global Influenza Preparedness Plan
CHAPTER THREE: FLU DIAGNOSTICS
Background
Exhbit 2: Influenza Test Innovations, 2009 (Company, Technology, Test Details,
Status)
Immunoassays
o Rapid Testing
o Market Performance of Rapid Test
o New Entrant Possiblity
o Conclusion: Impact of Swine Flu on Rapid Testing
Molecular Assays
o Molecular Influenza Detection Techniques
o PCR, Sequencing or Both
o Lessons and Market Impact of the H5N1 Epidemic
CHAPTER FOUR: PROGNOSIS FOR A/H1N1
Background
Pandemic - Where? When?
o 1976 Hsw1N1 Swine Flu Case
o Comparing Past Flu Epidemics to 2009
o International Reaction
Swine Flu and the IVD Industry

3. o Origin of Flu Virus Mixes
o PCR Test Development
o Late-Breaking Research Developments
o Use of Rapid Tests in Current Epidemic
CHAPTER FIVE: COMPANIES AND PRODCUTS IMPACTED BY SWINE FLU
EPIDEMIC
Immunoassays
o 3M Medical Diagnostics
o Becton, Dickinson and Company (BD)
o Genzyme Corporation
o Inverness Medical Innovations
o Meridian Bioscience, Inc.
o Quidel Corporation
o Remel, Inc.
o Response Biomedical Corporation
Molecular Tests
o Arbor Vita Corporation
o CombiMatrix Molecular Diagnostics (CMDX)
o Diagnostic HYBRIDS, Inc. (DHI)
o eGene Inc.
o Eiken Chemical Co., Ltd
o Life Technologies/Applied Biosystems/ Invitrogen Corporation (ABI)
o Lab21
o Laboratory Corporation of America Holdings (LabCorp)
o Luminex Corporation
o Nanogen
o Prodesse Inc.
o Qiagen N.V.
o Seegene Inc.
o Veredus Laboratories Pte
Available immediately for Online Download at
http://www.marketresearch.com/product/display.asp?productid=2241990
US: 800.298.5699

4. UK +44.207.256.3920
Int'l: +1.240.747.3093
Fax: 240.747.3004